Hepatitis C, Other Agents

• Hepatitis C Direct-acting Antivirals - Jan 28, 2016
• Hepatitis C Class Update - Jan 29, 2015
• Hepatitis C Class Update - Sep 23, 2014
• Hepatitis C Readiness to Refer Assessment - Jul 31, 2014
• Hepatitis C Advisory Committee Recommendations - Jul 31, 2014
• Hepatitis C Class Update - Jul 31, 2014
• Hepatitis C Class Update - Mar 27, 2014
• Class Update: Hepatitis C - Sep 26, 2013
• Class Review: Hepatitis C Agents - Jan 26, 2012

• August 2014 - New Hepatitis C Antiviral Therapies: How should they be used in clinical practice?
• August 2012 - Triple Therapy with the New Hepatitis C Protease Inhibitors: Challenges and Strategies

Y = preferred
N = non-preferred. Non-preferred drugs listed as N but without clinical drug use criteria are subject to the Non-Preferred Drugs in Select PDL Classes prior authorization criteria. New drugs will be listed as N until reviewed by the P&T Committee and are subject to the New Drug Policy.
V = voluntary non-preferred. Non-preferred mental health drugs are listed as V and prior authorization is not required.
Null (i.e. blank) = indicates the class or specific drug has not been reviewed for PDL placement.